Ongoing Phase I/II multicenter, open-label, multidose escalation trial investigating the safety and efficacy of the “L-RNA aptamer olaptesed pegol (NOX-A12) plus radiotherapy in newly diagnosed, unresectable glioblastoma”.Primary endpoints—safety/tolerability.Status: active; approved progression into combination therapy arms (+bevacizumab; + pembrolizumab, respectively). Here, IGKV2D-19 is linked to glioblastoma.